Rabies - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rabies - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Rabies - Pipeline Review, H1 2016', provides an overview of the Rabies pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Rabies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rabies
- The report reviews pipeline therapeutics for Rabies by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Rabies therapeutics and enlists all their major and minor projects
- The report assesses Rabies therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Rabies

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Rabies
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Rabies Overview 9
Therapeutics Development 10
Pipeline Products for Rabies - Overview 10
Pipeline Products for Rabies - Comparative Analysis 11
Rabies - Therapeutics under Development by Companies 12
Rabies - Therapeutics under Investigation by Universities/Institutes 14
Rabies - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Rabies - Products under Development by Companies 18
Rabies - Products under Investigation by Universities/Institutes 19
Rabies - Companies Involved in Therapeutics Development 20
Beijing Minhai Biotechnology Co., Ltd 20
Celltrion, Inc. 21
CureVac GmbH 22
Humabs BioMed SA 23
Kaketsuken K.K. 24
Kamada Ltd. 25
Medicago Inc. 26
Molecular Targeting Technologies, Inc. 27
NanoViricides, Inc. 28
Novavax, Inc. 29
PaxVax, Inc. 30
Prosetta Biosciences, Inc. 31
Sanofi Pasteur SA 32
Serum Institute of India Limited 33
Sinovac Biotech Ltd. 34
Trellis Bioscience, Inc. 35
VBI Vaccines Inc. 36
Zydus Cadila Healthcare Limited 37
Rabies - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
(Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CTP-19 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CV-8102 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KD-357 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Monoclonal Antibodies for Rabies - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Monoclonal Antibody for Rabies - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
nadorameran - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PAV-866 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
RabiCide-I - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
rabies (virus like particle) vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rabies [strain Wistar PM/WI 38-1503-3M] vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rabies immune globulin (human) - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
rabies vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
rabies vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
rabies vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
rabies vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
rabies vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
rabies vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
rabies vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
rabies vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Rabimabs - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SII RMab - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SO-57 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SOJB - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SYN-023 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Rabies - Recent Pipeline Updates 77
Rabies - Dormant Projects 80
Rabies - Product Development Milestones 81
Featured News & Press Releases 81
Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant 81
Dec 23, 2015: Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment 82
Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies 83
Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies 84
Aug 28, 2009: Rabies Vaccine Supply Update: IMOVAX Rabies Vaccine Availability 84
Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel 85
Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America 85
May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product 86
Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88

List of Tables

Number of Products under Development for Rabies, H1 2016 10
Number of Products under Development for Rabies - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Rabies - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 20
Rabies - Pipeline by Celltrion, Inc., H1 2016 21
Rabies - Pipeline by CureVac GmbH, H1 2016 22
Rabies - Pipeline by Humabs BioMed SA, H1 2016 23
Rabies - Pipeline by Kaketsuken K.K., H1 2016 24
Rabies - Pipeline by Kamada Ltd., H1 2016 25
Rabies - Pipeline by Medicago Inc., H1 2016 26
Rabies - Pipeline by Molecular Targeting Technologies, Inc., H1 2016 27
Rabies - Pipeline by NanoViricides, Inc., H1 2016 28
Rabies - Pipeline by Novavax, Inc., H1 2016 29
Rabies - Pipeline by PaxVax, Inc., H1 2016 30
Rabies - Pipeline by Prosetta Biosciences, Inc., H1 2016 31
Rabies - Pipeline by Sanofi Pasteur SA, H1 2016 32
Rabies - Pipeline by Serum Institute of India Limited, H1 2016 33
Rabies - Pipeline by Sinovac Biotech Ltd., H1 2016 34
Rabies - Pipeline by Trellis Bioscience, Inc., H1 2016 35
Rabies - Pipeline by VBI Vaccines Inc., H1 2016 36
Rabies - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 37
Assessment by Monotherapy Products, H1 2016 38
Assessment by Combination Products, H1 2016 39
Number of Products by Stage and Target, H1 2016 41
Number of Products by Stage and Mechanism of Action, H1 2016 43
Number of Products by Stage and Route of Administration, H1 2016 45
Number of Products by Stage and Molecule Type, H1 2016 47
Rabies Therapeutics - Recent Pipeline Updates, H1 2016 77
Rabies - Dormant Projects, H1 2016 80